PTSD Shows Different Biological Signatures in Men and Women: Endocannabinoid vs Inflammatory

Among 88 PTSD patients and 85 matched controls, male PTSD patients had significantly decreased levels of AEA, arachidonic acid, and OEA compared to male controls and female subgroups. Female PTSD patients showed elevated levels of IL-6 and IL-8 compared to other subgroups. These distinct profiles persisted after controlling for the FAAH gene variant and in the subgroup with comorbid depression.

Case-control study retrospectively selecting 88 PTSD patients and 85 sex- and age-matched healthy controls from the Mass General Brigham Biobank. Serum samples measured endocannabinoids (AEA, 2-AG, OEA, AA) and inflammatory markers (IL-1beta, IL-6, IL-8, IL-18, TNF-alpha, CRP). Analyses controlled for FAAH 385A genotype.

PTSD predominantly affects women, yet most biological research has focused on mixed samples. This study reveals that men and women with PTSD may have fundamentally different underlying biological disruptions: endocannabinoid depletion in men versus inflammatory elevation in women. This could explain why treatments work differently by sex.

If PTSD operates through different biological pathways in men versus women, then treatments targeting the endocannabinoid system (like cannabis) might be more effective for men, while anti-inflammatory approaches might better serve women. This has direct implications for the growing interest in cannabis-based PTSD treatments.

Cross-sectional biobank study cannot determine whether biomarker changes cause or result from PTSD. Retrospective selection may introduce bias. Serum endocannabinoid levels may not reflect brain levels. Cannot determine whether differences existed before PTSD onset. Single timepoint measurement.